Innopharmax Inc (4172):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Innopharmax Inc (4172) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7970
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:台湾
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Innopharmax Inc (InnoPharmax), a subsidiary of Synmosa Biopharma Corp is a pharmaceutical company that develops and commercializes products for the treatment of oncology and specialty. The company provides anti-infection agents, oncology agents, contrast agents, immunological agents and drugs for rare diseases, among others. It offers pipeline products such as agents for metabolic diseases, CNS agents and urology agents, among others. Innopharmax develops and acquires drug candidates for further clinical development and commercialization. The company also undertakes contract formulation development of pharmaceuticals including immediate release formulations to alternative dosage designs and controlled release formulations. It markets its products through its distributors. InnoPharmax is headquarterd in Taipei, Taiwan.

Innopharmax Inc (4172) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Innopharmax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Innopharmax Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Innopharmax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Innopharmax Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Innopharmax Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Innopharmax Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Innopharmax Raises Funds in Venture Financing 10
Licensing Agreements 11
InnoPharma Enters Into Licensing Agreement With Fresenius Kabi For Acetylcysteine Solution 11
Equity Offering 12
Innopharmax to Raise up to USD5.2 Million in Public Offering 12
Innopharmax Raises USD8 Million in Rights Offering of Shares 13
Innopharmax Completes IPO 14
Acquisition 15
Synmosa and InnoPharmax Acquire Minority Stake in Seven Star Pharma 15
Innopharmax to Acquire 16% Stake in Pharma Company 16
Innopharmax Inc – Key Competitors 17
Innopharmax Inc – Locations And Subsidiaries 18
Head Office 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
Innopharmax Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Innopharmax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Innopharmax Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Innopharmax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Innopharmax Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Innopharmax Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Innopharmax Raises Funds in Venture Financing 10
InnoPharma Enters Into Licensing Agreement With Fresenius Kabi For Acetylcysteine Solution 11
Innopharmax to Raise up to USD5.2 Million in Public Offering 12
Innopharmax Raises USD8 Million in Rights Offering of Shares 13
Innopharmax Completes IPO 14
Synmosa and InnoPharmax Acquire Minority Stake in Seven Star Pharma 15
Innopharmax to Acquire 16% Stake in Pharma Company 16
Innopharmax Inc, Key Competitors 17

List of Figures
Innopharmax Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Innopharmax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Innopharmax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Innopharmax Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Innopharmax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Innopharmax Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Innopharmax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Innopharmax Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Innopharmax Inc (4172):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • ALK-Abello AS (ALK B):企業の財務・戦略的SWOT分析
    ALK-Abello AS (ALK B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • VINCI Energies:企業のM&A・事業提携・投資動向
    VINCI Energies - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's VINCI Energies Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Sanofi SA:企業のM&A・事業提携・投資動向
    Sanofi SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sanofi SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Neovasc Inc (NVC):企業の財務・戦略的SWOT分析
    Summary Neovasc Inc (Neovasc) is a medical device manufacturing company that manufactures, develops, and sells cardiovascular disease products. The company’s products include Neovasc reducer, Neovasc tiara, and Neovasc tissue products. Its Neovasc tiara is a novel transcatheter device that is design …
  • Comision Federal de Electricidad-エネルギー分野:企業M&A・提携分析
    Summary Comision Federal de Electricidad (CFE) is a Mexican state owned power utility. It carries out the generation, transmission, distribution, supply and commercialization of electricity. The company generates electricity through various energy sources including thermal, hydro, coal-fired, wind, …
  • Constant Contact, Inc.:企業の戦略・SWOT・財務分析
    Constant Contact, Inc. - Strategy, SWOT and Corporate Finance Report Summary Constant Contact, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Qatar Electricity & Water Co QPSC (QEWS):企業の財務・戦略的SWOT分析
    Qatar Electricity & Water Co QPSC (QEWS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Neuro Kinetics Inc-医療機器分野:企業M&A・提携分析
    Summary Neuro Kinetics Inc (NKI) is a medical device company that offers eye tracking technology and non-invasive neuro-otologic diagnostic testing solutions. The company provides products such as vestibular and neuro-otologic testing systems, VNG diagnostic systems, VOF eye tracking systems, softwa …
  • TKH Group NV (TWEKA):企業の財務・戦略的SWOT分析
    TKH Group NV (TWEKA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Watchstone Group plc (WTG):企業の財務・戦略的SWOT分析
    Summary Watchstone Group plc (Watchstone) formerly Quindell Plc, is a technology company that offers services such as software; consulting and technology enabled outsourcing services. The company provide solutions such as Hubio, pt Health, ingenie, InnoCare, QuoteSupermarket, and others. It provides …
  • Pharmaxis Ltd (PXS)-医療機器分野:企業M&A・提携分析
    Summary Pharmaxis Ltd (Pharmaxis) is a pharmaceutical research company that develops and commercialize healthcare products. The company offers products such as aridol which identify twitchy and assist in diagnosing and managing asthma, and bronchitol which restores normal lung hydration, improves lu …
  • Nano Intelligent Biomedical Engineering Corp (138610):医療機器:M&Aディール及び事業提携情報
    Summary Nano Intelligent Biomedical Engineering Corp (NIBEC) is a venture firm. The firm manufacture of tissue regeneration devices. It aims to research ideas for tissue regeneration treatments and to develop and manufacture devices for practical use. NIBEC offers bio fusion peptide-based products, …
  • Maxwell Technologies Inc. (MXWL):電力:M&Aディール及び事業提携情報
    Summary Maxwell Technologies, Inc. (Maxwell) formerly Maxwell Laboratories, Inc., is a manufacturer of capacitor-based energy storage systems and power delivery solutions. The company develops, manufactures and markets energy storage and power delivery products for transportation and other applicati …
  • MEC Resources Ltd (MMR):企業の財務・戦略的SWOT分析
    MEC Resources Ltd (MMR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Medicom Innovation Partner as-医療機器分野:企業M&A・提携分析
    Summary Medicom Innovation Partner a/s (Medicom), formerly Bang & Olufsen Medicom, a subsidiary of Phillips-Medisize Corp, is a medical device company that develops electronic-based drug delivery and connected health systems. The company offers services such as device strategy and direction, device …
  • Ameritas Mutual Holding Company:企業の戦略的SWOT分析
    Ameritas Mutual Holding Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Fluxion Biosciences Inc:医療機器:M&Aディール及び事業提携情報
    Summary Fluxion Biosciences Inc (Fluxion) is a provider of analytical instruments for functional cellular analyses. The company’s liquid biopsy technologies include IsoFlux CTC liquid biopsy system, ERASE-Seq variant caller for liquid biopsies and the Spotlight 59 for ultra-sensitive NGS mutation de …
  • Petroleos Mexicanos:石油・ガス:M&Aディール及び事業提携情報
    Summary Petroleos Mexicanos (PEMEX) is a state-owned integrated oil and gas company. It operates across the value chain of oil and gas industry, from exploration and production to processing, logistics and marketing. PEMEX also produces and distributes a wide range of petrochemical products. The com …
  • HMicro Inc-医療機器分野:企業M&A・提携分析
    Summary HMicro Inc (HMicro) is a medical device company that offers wireless sensor solutions. The company offers REACH wireless module, a wireless silicon platform that offers fully disposable and wearable wireless sensor patches for a range of professional clinical procedures in hospitals, clinics …
  • Plexus Corp (PLXS):企業の財務・戦略的SWOT分析
    Plexus Corp (PLXS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆